Golden Gate Capital has announced that ArrMaz has entered into a definitive agreement to be acquired by Arkema Group for approximately US$570 million.
Arkema is a global manufacturer of specialty chemicals and advanced materials used across a range of industries. ArrMaz’s management team, led by Chief Executive Officer Dave Keselica, will continue to lead ArrMaz after the transaction is completed.
ArrMaz provides chemical process aids and additives formulated to improve their customers’ products and processes.
Dave Keselica said: “We are excited to join forces with Arkema after a successful long-term partnership with Golden Gate Capital. Under their ownership, we expanded and improved the technical performance of our core product suite, entered attractive new markets such as lithium flotation and proppant dust control, and expanded our research and development capabilities and facilities worldwide. We look forward to continuing to provide our customers with the highest quality chemical solutions and unrivalled end-to-end support as we enter this next chapter of our growth.”
Dave Thomas, Managing Director at Golden Gate Capital, said: “We thank Dave Keselica and the entire ArrMaz team for a fantastic partnership over the past six years. During that time, ArrMaz significantly expanded its global footprint, particularly in the Middle East and Africa, through acquisitions and new plant openings, while accelerating innovation across their markets. We are confident that Arkema will be a great partner for ArrMaz’s future growth.”
The transaction is expected to close in the summer of 2019, subject to customary closing conditions.
Lazard Middle Market and Moelis & Company acted as financial advisors to ArrMaz and Nob Hill Law Group, and Kirkland & Ellis served as legal advisors to Golden Gate Capital and ArrMaz. The Valence Group served as financial advisor to Arkema.
Read the article online at: https://www.hydrocarbonengineering.com/petrochemicals/16052019/arkema-group-to-acquire-arrmaz/
You might also like
The first 100% SAF transatlantic flight by a commercial airline was made possible with the BioForming® technology invented by Virent and jointly developed for commercialisation by Virent and Johnson Matthey.